A. Farland

Effects of Shear Stress on Production of FVIII and vWF in a Cell-Based Therapeutic for Hemophilia A

A. Atala, A. Skardal, Julio Aleman, 2021, Frontiers in Bioengineering and Biotechnology.

Defining the Optimal FVIII Transgene for Placental Cell-Based Gene Therapy to Treat Hemophilia A

A. Atala, G. Almeida-Porada, C. Porada, 2020, Molecular therapy. Methods & clinical development.

Long‐term management of acquired thrombotic thrombocytopenic purpura using serial plasma ADAMTS13 measurements

J. Owen, A. Farland, M. A. Knovich, 2012, European journal of haematology.

Comparison of different gene addition strategies to modify placental derived-mesenchymal stromal cells to produce FVIII

C. Bishop, C. Langefeld, A. Atala, 2022, Frontiers in Immunology.

Investigating Optimal Autologous Cellular Platforms for Prenatal or Perinatal Factor VIII Delivery to Treat Hemophilia A

C. Rodman, A. Atala, G. Almeida-Porada, 2021, Frontiers in Cell and Developmental Biology.

Race, Rituximab, and Relapse in TTP.

Gustaaf G. de Ridder, K. McCrae, Shruti Chaturvedi, 2022, Blood.

Successful treatment of intravenously abused oral Opana ER‐induced thrombotic microangiopathy without plasma exchange

K. Batt, J. Owen, P. Miller, 2014, American journal of hematology.

Implementation of Individualized Pain Care Plans Decreases Length of Stay and Hospital Admission Rates for High Utilizing Adults with Sickle Cell Disease.

Amber K. Brooks, R. Hurley, A. Farland, 2021, Pain medicine.

Acute Thrombotic Microangiopathy and Cortical Necrosis Following Administration of Alemtuzumab: A Case Report.

M. Rocco, P. Persad, A. Farland, 2019, American journal of kidney diseases : the official journal of the National Kidney Foundation.